CClinicalTrials.gg
Status unknownNCT04073758ARNRDUpdated Mar 20, 2020

Comparison of Analgesic Requirements in Patients Receiving Nuss Operation Using 2 Different Anesthetic Adjuvants

An interventional study of Dexmedetomidine in Chest Wall Disorder, sponsored by Jung Min Koo. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-03-20.

Sponsored by Jung Min Koo · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Nowadays, general anaesthesia is carried under "balanced anesthesia technique" in which many anesthetic adjuvants are used simultaneously, including opioid analgesics in order to reduce the amount of inhalation agents. The most popular adjuvants used are remifentanil, which is an opioid analgesic, and dexmedetomidine. Both of these agents are short acting, can be infused with targeted concentrations, excreted shortly from the body with stable hemodynamics.

Remifentanil, when infused for more than 2 hours, causes hyperalgesia to increase the amount of pain postoperatively as well as the amount of opioid analgesics. However, dexmedetomidine does not cause hyperalgesia and is known to have an opioid -sparing effect. In our center.

In this study, we aim to compare the effects of remifentanil and dexmedetomidine on postoperative pain in patients undergoing Nuss procedure, which is a very painful operation on the chest wall.

02

Conditions studied

  • Chest Wall Disorder

Keywords

  • Pectus Excavatum
03

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adults aged >20
  2. Patients undergoing Nuss bar operation (pectus excavatum repair surgery)
  3. American Society of Anesthesiologists classification I \~ III

Exclusion criteria

Exclusion Criteria:

  1. Drug abuse history
  2. Chronic pain in need of continuous opioid analgesics administration
  3. History of psychiatric diseases
  4. Preoperative bradycardia (heart rate \< 50/min) or arrythmia
  5. Cardiac diseases other than diabetes or hypertension - coronary artery disease, ischemic heart disease
  6. Moderate liver or kidney dysfunction
  7. Pregnant or breast feeding women
  8. Hypersensitivity to the study drugs
  9. Patients who do not agree to participate
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
62 participants (estimated)

Study arms

  • Sham comparator
    Remifentanil group

    In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted Minimal Alveolar Concentration (MAC). As explained above, remifentanil is infused with Target Controlled Infusion pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Remifentanil is usually infused with the effect site concentration of 2.0 to 6.0 ng/ml during general anesthesia. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, remifentanil infusion will be stopped.

    Drug: Dexmedetomidine

  • Active comparator
    Dexmedetomidine group

    In both interventional groups, Sevoflurane is used as an inhalational agent, in 0.5-1.5% age-adjusted MAC (Minimal Alveolar Concentration). As explained above, dexmedetomidine is infused with syringe pump, and concentration is adjusted so that Bispectral index (BIS) is maintained as 40-60, which means that the patients are maintained in general anesthesia. Dexmedetomidine is loaded for 10 minutes in 1mcg/kg, and then infusion rate is set between 0.4 to 0.6mcg/kg/hour for this study. If bradycardia or hypotension develops due to remifentanil infusion, the infusion rate could be reduced, or inotropic, vasopressor, anticholinergic agents can be used (ephedrine, atropine, etc.) to correct the side effects of the drug, or the drug infusion can even be ceased. At the end of the surgery when skin closure starts, dexmedetomidine infusion will be stopped.

    Drug: Dexmedetomidine

Interventions

  • DrugDexmedetomidine

    Comparing effects of remifentanil versus dexmedetomidine

    Also known as: Remifentanil

05

What researchers measure

Primary outcomes

  1. Visual Analogue Scale

    Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.

    Time frame: Between 1~6 hours postoperatively.

  2. Visual Analogue Scale

    Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.

    Time frame: Between 6~12 hours postoperatively.

  3. Visual Analogue Scale

    Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.

    Time frame: Between 12~24 hours postoperatively.

  4. Visual Analogue Scale

    Pain scale ranges from 0 to 10. 0 means no pain at all, and 10 being the most severe pain anyone can imagine.

    Time frame: Between 24~48 hours postoperatively.

Secondary outcomes

  1. Amount of postoperative intravenous patient controlled analgesics (PCA) used

    Time frame: At 60 minutes after the end of surgery

  2. Amount of fentanyl used postoperatively at the recovery unit

    Amount in micgrograms per wegith in kilograms (migrogram/kilogram)

    Time frame: At 60 minutes after the end of surgery

  3. Time needed for postoperative rescue opioid analgesics

    Time frame: At 60 minutes after the end of surgery

  4. Amount of remifentanil or dexmedetomidine used intraoperatively

    Time frame: Immediately at the end of the surgery

  5. Intraoperative hemodynamic change: Systolic blood pressure

    Time frame: 1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room

  6. Intraoperative hemodynamic change: Diastolic blood pressure

    Time frame: 1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room

  7. Intraoperative hemodynamic change: mean blood pressure

    Time frame: 1 minute after monitoring (of blood pressure, heart rate, pulse oxymeter and electrocardiogram) starts, when the patient arrives at the operating room

  8. Intraoperative hemodynamic change: heart rate

    Time frame: 30 minutes after the induction of anesthesia

  9. Intraoperative hemodynamic change: mean blood pressure

    Time frame: At the end of the surgery, average of 90minutes after the induction of anesthesia

  10. Intraoperative hemodynamic change: heart rate

    Time frame: At the end of the surgery, average of 90minutes after the induction of anesthesia

  11. Intraoperative hemodynamic change: Systolic blood pressure

    Time frame: At the end of the surgery, average of 90minutes after the induction of anesthesia

  12. Intraoperative hemodynamic change: Diastolic blood pressure

    Time frame: At the end of the surgery, average of 90minutes after the induction of anesthesia

  13. Rescue drugs (inotropics or vasopressors) used in order to correct hypotension or bradycardia

    Time frame: Intraoperatively

  14. Postoperative complications

    Number of events that happened to the patient: e.g. Yes or No, and how many times. Nausea/vomiting, hypotension, respiratory depression, urinary retension, dizziness, transient cease in use of intravenous patient controlled analgesics (PCA)

    Time frame: Between 1~6 hours postoperatively

  15. Postoperative complications

    Number of events that happened to the patient: e.g. Yes or No, and how many times. Nausea/vomiting, hypotension, respiratory depression, urinary retension, dizziness, transient cease in use of intravenous patient controlled analgesics (PCA)

    Time frame: Between 12~24 hours postoperatively

  16. Postoperative complications

    Number of events that happened to the patient: e.g. Yes or No, and how many times. Nausea/vomiting, hypotension, respiratory depression, urinary retension, dizziness, transient cease in use of intravenous patient controlled analgesics (PCA)

    Time frame: Between 24~48 hours postoperatively

06

Study locations

1 site
  • Jung Min Koo
    Seoul, Korea, Republic of
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04073758
Lead sponsor
Jung Min Koo
Responsible party
Jung Min Koo (Principal Investigator, Seoul St. Mary's Hospital) — Sponsor-investigator
First posted
Aug 29, 2019
Start date
Sep 2, 2019
Primary completion
Feb 21, 2021 (estimated)
Completion
Feb 28, 2021 (estimated)
Last update
Mar 20, 2020

Study contacts

Jung Min Koo, M.D
principal investigator · Data recruitment

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion